Clinical Trial Update: Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg [Phase 2]

View source ↗

Summary

Phase 2 trial of Firmonertinib in EGFR-mutant advanced non-small cell lung cancer shows disease stabilization after an 8-week induction with 80 mg.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING